These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. J Am Coll Cardiol; 2005 Mar 15; 45(6):941-6. PubMed ID: 15766833 [Abstract] [Full Text] [Related]
5. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Büllesfeld L, Gerckens U, Müller R, Grube E. Z Kardiol; 2003 Oct 15; 92(10):825-32. PubMed ID: 14579046 [Abstract] [Full Text] [Related]
6. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials. Sanchez-Recalde A, Moreno R, Barreales L, Rivero F, Galeote G, Jimenez-Valero S, Calvo L, López de Sá E, López-Sendón JL. J Invasive Cardiol; 2008 Aug 15; 20(8):417-22. PubMed ID: 18688067 [Abstract] [Full Text] [Related]
9. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A. Circulation; 2007 Jun 26; 115(25):3181-8. PubMed ID: 17562952 [Abstract] [Full Text] [Related]
15. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, Stone GW. Am Heart J; 2005 Dec 19; 150(6):1163-70. PubMed ID: 16338253 [Abstract] [Full Text] [Related]